Latest Ohio State University Comprehensive Cancer Center Stories
Researchers have discovered a restricted pattern of molecules that differentiate early-stage breast tumors from invasive, life-threatening cancer.
According to a new study, oral infections with the human papillomavirus (HPV) are more common in men than women.
New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.
A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer.
The study shows how normal cells in tumors can enhance the growth of the tumor’s cancer cells after losing an important tumor suppressor gene called Pten.
A new study has identified a gene mutation that researchers estimate dates back to 11,600 B.C., making it the second oldest human disease mutation yet discovered.
Men are three times more likely than women to develop a common form of skin cancer but medical science doesn’t know why.
A new study suggests that blocking cancer cells' access to cholesterol may offer a new strategy for treating glioblastoma, the most common and deadly form of brain cancer, and perhaps other malignancies.
Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life.
CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S.